Yazar "Karakus, A." seçeneğine göre listele

Listeleniyor 1 - 10 / 10
  • [ X ]
    Öğe
    ASSESSMENT OF THE UNDERLYING CAUSES OF IMMUNE THROMBOCYTOPENIA: TEN YEARS EXPERIENCE
    (Pergamon-Elsevier Science Ltd, 2016) Dal, M.; Karakus, A.; Dal, T.; Aydin, B.; Hattapoglu, E.; Ekmen, M.; Ulas, T.
    [Abstract Not Available]
  • [ X ]
    Öğe
    CLASSIFICATION OF NON-HODGKIN LYMPHOMA IN SOUTHEAST TURKEY: A REVIEW OF 550 CASES
    (Pergamon-Elsevier Science Ltd, 2016) Ekmen, M.; Dal, M.; Karakus, A.; Buyukbayram, H.; Ayyildiz, O.
    [Abstract Not Available]
  • [ X ]
    Öğe
  • [ X ]
    Öğe
    FASCIOLA HEPATICA ASSOCIATED WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE
    (Pergamon-Elsevier Science Ltd, 2014) Karakus, A.; Dal, M. S.; Ekmen, M. O.; Yildirim, R.; Dal, T.; Ayyildiz, O.
    [Abstract Not Available]
  • [ X ]
    Öğe
    A HEREDITARY HEMORAGIC TELANGIECTASIA (OSLER-WEBER-RENDU DISEASE) PRESENTING WITH SEVERE ANEMIA
    (Pergamon-Elsevier Science Ltd, 2014) Ekmen, M. O.; Dal, M. S.; Karakus, A.; Ayyildiz, O.
    [Abstract Not Available]
  • [ X ]
    Öğe
    IS THE ELTROMPOBAG TREATMENT SAFE OR EFFECTIVE FOR REFRACTORY CHRONIC IMMUNE THROMBOCYTOPENIA PATIENTS?
    (Pergamon-Elsevier Science Ltd, 2016) Dal, M.; Karakus, A.; Cakar, M.; Ulu, B.; Hattapoglu, E.; Ekmen, M.; Ulas, T.
    [Abstract Not Available]
  • [ X ]
    Öğe
    Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with first-line cisplatin-based chemotherapy: A retrospective analysis of single institution
    (Imprimatur Publications, 2012) Inal, A.; Kaplan, M. A.; Kucukoner, M.; Karakus, A.; Isikdogan, A.
    Purpose: Non-small cell lung cancer (NSCLC) makes up 80-85% of all lung cancers cases. Lung cancer in older individuals is frequently undertreated. Patients eligible for cisplatin-based chemotherapy should be selected carefully. The aim of this retrospective single-center study was to evaluate prognostic factors for overall survival (OS) in elderly (>= 65 years) patients with advanced NSCLC who received first-line cisplatin-based chemotherapy. Methods: We retrospectively reviewed 110 elderly patients with locally advanced or metastatic NSCLC who had been administered cisplatin-based first-line chemotherapy between December 2004 and November 2011. Seventeen potential prognostic variables were chosen for analysis. Univariate and multivariate analyses were conducted to identify prognostic factors associated with OS. Results: Among the 17 variables of univariate analysis, 4 were identified to have prognostic significance for OS: comorbidities (p<0.001), Eastern Cooperative Oncology Group (ECOG) performance status (PS) (p=0.02), first-line chemotherapy cycles (p<0.001) and serum albumin level (p=0.04). Multivariate analysis showed that only ECOG PS (p=0.01) was independent prognostic factor for OS. Conclusion: PS was important prognostic factor in elderly patients with advanced NSCLC. The findings of this study may facilitate pretreatment prediction of OS and therefore can be used for selecting the most appropriate treatment for elderly patients.
  • [ X ]
    Öğe
    Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with advanced non-small cell lung cancer: Single center experience
    (Imprimatur Publications, 2012) Inal, A.; Kucukoner, M.; Kaplan, M. A.; Urakci, Z.; Karakus, A.; Komek, H.; Dostbil, Z.
    Purpose: The purpose of this retrospective single-center study was to evaluate the prognostic implication on overall survival (OS) of the F-18 FDG PET scan in locally advanced or metastatic non small cell lung cancer (NSCLC) patients. Methods: We retrospectively reviewed 120 locally advanced or metastatic NSCLC patients (December 2004-November 2011) treated/followed at the Dicle University, School of Medicine, Department of Medical Oncology. SUVmax and other potential prognostic variables (n=18) were chosen for analysis. Univariate and multivariate analyses were conducted to identify prognostic factors for OS. Results: Among 18 variables of univariate analysis, 6 were identified to bear prognostic significance: sex (p=0.01), performance status (PS) (p=0.03), stage (p=0.04), bone metastases (p=0.002), serum albumin (p=0.01) and blood glucose level (p=0.03). Multivariate analysis showed that PS, bone metastases and serum albumin level were independent prognostic factors for OS (p=0.01, p=0.004, p=0.003, respectively). Conclusion: PS, serum albumin levels and bone metastases were independent prognostic factors, while FDG uptake of the primary lesion was not associated with prognosis of OS in locally advanced or metastatic NSCLC patients.
  • [ X ]
    Öğe
    RETROSPECTIVE ANALYSIS OF ELTROMBOPAG FOR THE TREATMENT OF REFRACTORY PRIMARY IMMUNE THROMBOCYTOPENIA IN THE SOUTH OF TURKEY
    (Pergamon-Elsevier Science Ltd, 2014) Dal, M. S.; Hattaboglu, E.; Karakus, A.; Ekmen, M. O.; Ayyildiz, O.
    [Abstract Not Available]
  • [ X ]
    Öğe
    Serum uric acid and inflammation in patients with immune thrombocytopenic purpura: preliminary results
    (Verduci Publisher, 2015) Dal, M. S.; Karakus, A.; Aydin, B. B.; Ekmen, M. O.; Ulas, T.; Ayyildiz, O.
    OBJECTIVE: The purpose of this study was to evaluate the uric acid (UA) and Creactive protein (CRP) levels in patients with immune thrombocytopenic purpura (ITP). PATIENTS AND METHODS: Forty patients with newly diagnosed ITP and 40 healthy individuals were enrolled in the study. The patients were divided into two groups; group 1 (n = 40) consisted of patients with ITP, and group 2 (n = 40) consisted of healthy subjects. UA and CRP levels were measured in the blood samples from them. RESULTS: There were no statistical differences in gender, age and body mass index between two groups (p > 0.05 for all). Compared to group 2, group 1 had significantly higher UA levels (p = 0.002), whereas CRP levels were not significantly different (p > 0.05). In ITP patients, serum UA and CRP levels significantly correlated with low platelet count (r = -0.362, p = 0.022; r = -0.383, p = 0.015, respectively); and UA levels significantly correlated with CRP levels (r = 0.436, p = 0.005). CONCLUSIONS: The present study showed that UA levels increased in patients with ITP and negatively correlated with platelet counts. UA levels might be a mediator of inflammation via enhanced production of inflammatory cytokines; they might also be a potential mediator of low platelet count, and could play a pathophysiological role in the development of ITP.